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Abstract Background: Nicotine dependence is the major
obstacle for smokers who want to quit. Guidelines have
identiﬁed ﬁve eﬀective ﬁrst-line therapies, four nicotine
replacement therapies (NRTs)—gum, patch, nasal spray
and inhaler—and bupropion. Studying the extent to
which these various treatments are cost-eﬀective requires
additional research.
Objectives: To determine cost-eﬀectiveness (CE) ratios of
pharmacotherapies for nicotine dependence provided by
general practitioners (GPs) during routine visits as an
adjunct to cessation counselling.
Methods: We used a Markov model to generate two
cohorts of one-pack-a-day smokers: (1) the reference
cohort received only cessation counselling from a GP
during routine oﬃce visits; (2) the second cohort received
the same counselling plus an oﬀer to use a pharmacolog-
ical treatment to help them quit smoking. The eﬀective-
ness of adjunctive therapy was expressed in terms of the
resultant diﬀerential in mortality rate between the two
cohorts. Data on the eﬀectiveness of therapies came from
meta-analyses, and we used odds ratio for quitting as the
measure of eﬀectiveness. The costs of pharmacotherapies
were based on the cost of the additional time spent by
GPs oﬀering, prescribing and following-up treatment,
and on the retail prices of the therapies. We used the
third-party-payer perspective. Results are expressed as
the incremental cost per life-year saved.
Results: The cost per life-year saved for only counselling
ranged from 385 to 622 for men and from 468 to
796 for women. The CE ratios for the ﬁve pharmaco-
logical treatments varied from 1768 to 6879 for men,
and from 2146 to 8799 for women. Signiﬁcant varia-
tions in CE ratios among the ﬁve treatments were
primarily due to diﬀerences in retail prices. The most
cost-eﬀective treatments were bupropion and the patch,
and, then, in descending order, the spray, the inhaler
and, lastly, gum. Diﬀerences in CE between men and
women across treatments were due to the shape of their
respective mortality curve. The lowest CE ratio in men
was for the 45- to 49-year-old group and for women in
the 50- to 54-year-old group. Sensitivity analysis showed
that changes in treatment eﬃcacy produced eﬀects only
for less-well proven treatments (spray, inhaler, and
bupropion) and revealed a strong inﬂuence of the
discount rate and natural quit rate on the CE of
pharmacological treatments.
Conclusion: The CE of ﬁrst-line treatments for nicotine
dependence varied widely with age and sex and was
sensitive to the assumption for the natural quit rate.
Bupropion and the nicotine patch were the two most
cost-eﬀective treatments.
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Introduction
Tobacco is the leading cause of preventable death in
developed countries. Lowering smoking prevalence is
the primary goal in tobacco control. There are two core
approaches to reducing prevalence—preventing non-
smokers from starting and encouraging current smokers
to quit. This study focuses on the second component of a
comprehensive approach to tobacco control, the cost-
eﬀectiveness of pharmacological smoking cessation aids.
Nicotine dependence is what anchors smokers to their
habits and, for many, prevents them from quitting [1].
Eur J Clin Pharmacol (2003) 59: 201–206
DOI 10.1007/s00228-003-0610-6
Jacques Cornuz Æ Christophe Pinget Æ Allison Gilbert
Fred Paccaud
J. Cornuz (&) Æ A. Gilbert Æ F. Paccaud
Institute of Social and Preventive Medicine,
University of Lausanne, rue du Bugnon 17,
CH-1005, Lausanne, Switzerland
E-mail: Jacques.Cornuz@chuv.hospvd.ch
Tel.: +41-21-3140506
Fax: +41-21-3147244
J. Cornuz
Department of Medicine and Outpatient clinic,
University Hospital, 1010 Lausanne, Switzerland
C. Pinget
Institute of Health Economics and Management,
University of Lausanne, Champ de l’Air, rue du Bugnon 21,
1005 Lausanne, Switzerland
More than half of all regular smokers express a desire to
quit smoking, and most of them report having tried
unsuccessfully to give up the habit [2]. It has been re-
cently emphasised that studying the extent to which
various tobacco dependence treatments are cost-eﬀective
requires additional research [3]. Counselling and phar-
macological cessation therapies have been proven to be
eﬃcacious as aids for smoking cessation, nearly doubling
a smoker’s chances of quitting successfully [4, 5, 6, 7].
Recent clinical practice guidelines have identiﬁed ﬁve
ﬁrst-line therapies [3]. These treatments include four
nicotine replacement therapies (NRTs)—gum, patch,
nasal spray and inhaler—and bupropion, an anti-
depressant which has recently been demonstrated as an
eﬀective treatment for nicotine dependence. In today’s
political and economic climates, marked by ﬁerce com-
petition for limited resources, eﬀectiveness alone is no
longer suﬃcient support for the recommendation of new
or preferred interventions. Instead, it is also requisite to
provide evidence for cost-eﬀectiveness when presenting
policy options that are considered superior to those al-
ready in place or to none at all. Few studies—all based
on data from Anglo-Saxon countries—have shown that
NRT is both eﬀective in practice and cost-eﬀective rel-
ative to other common health interventions that are
generally funded by third-party payers [8, 9, 10]. How-
ever, to our knowledge, no studies have assessed all
available ﬁrst-line pharmacological smoking cessation
treatments, i.e., NRT and bupropion. We conducted this
analysis as a part of a comprehensive approach to
smoking cessation in a European country [11].
Methods
Calculation of eﬀectiveness
We calculated the cost-eﬀectiveness of general practitioners (GPs)
providing their patients each of the ﬁve ﬁrst-line pharmacological
smoking cessation treatments as an adjunct to cessation counsel-
ling. We supposed that GPs provided their smoking patients
opportunistic cessation counselling during routine oﬃce visits and
oﬀered treatment to those for whom it was indicated. Clinical
guidelines indicate pharmacological cessation therapy only for
smokers who consume at least 10–15 cigarettes per day. The vast
majority of daily smokers visiting a GP smoke on average a pack a
day [12, 13, 14]. Therefore, we included in our simulated cohorts
only patients who smoked, on average, 20 cigarettes per day.
We used a computer-simulated Markov model to generate two
cohorts of identical smokers [15]. The reference cohort received
only cessation counselling from a GP during routine oﬃce visits.
The second cohort received the same counselling plus an oﬀer to
use a pharmacological treatment to help them quit smoking. The
counselling-plus-treatment simulation was run for each of the ﬁve
therapies. As a result, the two cohorts had diﬀerent quit rates,
which further indicated diﬀerent mortality rates. We expressed the
eﬀectiveness of adjunctive treatment in terms of this resultant dif-
ferential in mortality rates between the two cohorts. Details of the
model can be obtained either directly from the authors upon re-
quest or through the following web address (http://www.hos-
pvd.ch/iumsp/download/ﬁles/rapport/markovmodel.pdf).
The total cost of oﬀering pharmacological treatments was based
on the cost of the additional time spent by GPs oﬀering, prescribing
and following-up pharmacological treatment, and on the retail
prices of the therapies. The results were expressed as the incre-
mental cost per life-year saved (with both costs and life-years dis-
counted, as described below) that was attributable to the oﬀer,
availability, and use of pharmacological treatments, which included
the costs associated with patients who were not successful in their
treatment-aided quit attempts. Table 1 lists the input variables,
base-case assumptions, and ranges for sensitivity analysis used in
our study. We assumed a natural quit rate (i.e., cessation without
intervention) among smokers of 2.5%. This rate reﬂected the esti-
mated probability of quitting smoking over the course of 1 year in
Switzerland, as well as in other Western countries [12, 16].
Studies have shown that 50–70% of smokers would like to quit
smoking [2, 13]. Yet, according to the Stages-of-Change model, a
much smaller proportion of these smokers are in the preparation
stage—truly ready to make a serious quit attempt—and therefore
appropriate candidates for treatment [17]. We made the assumption
that 25% of current smokers were in the preparation stage for
quitting [18] and used it in the Markov model. We derived the
eﬀectiveness of counselling and NRT from the results of two
published meta-analyses [4, 5]. We based our analysis of bupropion
on the eﬃcacy trial conducted by Jorenby et al., which yielded
similar results to a recent meta-analysis based on two bupropion
eﬃcacy trials performed by the US Department of Health and
Human Services (DHHS) [3, 6]. Each of our reference studies based
its measurement of cessation status on the point prevalence at
1 year of abstinence.
Table 1 Variables used in the
analysis
*Odds ratio for smoking cessa-
tion at 1 year, relative to no
intervention
**Incremental odds ratio for
cessation at 1 year, relative to
counselling only (identical OR
for women and men)
Variable Base case (range for sensitivity analysis)
Natural cessation rate among all smokers, % 2.5 (1–4)
Proportion of smokers in ‘‘preparation’’ stage, % 25 (10–40)
OR* counselling only 1.73 (1.46–2.03)
OR** nicotine gum 1.63 (1.49–1.79)
OR** nicotine patch 1.79 (1.60–2.01)
OR** nicotine spray 2.35 (1.63–3.38)
OR** nicotine inhaler 2.14 (1.44–3.18)
OR** bupropion 2.30 (1.40–3.90)
Smokers still under treatment after ﬁrst month, % 50 (40–60)
Smokers still under treatment after second month, % 20 (15–25)
Lifetime probability of relapse after 1 year
of abstinence, %
35 (10–50)
Time required for counselling, min 10 (5–15)
Total additional physician time required, min 90 (70–110)
Cost per hour of physicians’ time, Euro US $65 (55.25–74.75)/ Euro 61.25
(52.06–70.44)
Discount rate, % 3 (0–5)
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We used odds ratio for quitting as the measure of eﬀectiveness
for each treatment. We assumed that quit odds ratios were the same
for men and women, the rationale for which has been presented in
existing studies [5]. We calculated the quit rates for the pharma-
cological treatments as adjuncts to counselling by multiplying the
quit odds ratios for each of the respective treatments by the odds of
quitting for counselling only. For each treatment, we used the 95%
conﬁdence intervals for eﬀectiveness as the range for our sensitivity
analysis.
The long-term risk of relapse for former smokers has not been
well documented. Existing long-term follow-up data suggest that of
the subjects who have been abstinent for 1 year, approximately
30% will relapse some time during the following 5 years [19, 20].
Relapse after 5 years does occur, but the rate is insigniﬁcantly low
[19, 20]. From previous studies, we adopted the conservative
assumption of a 35% lifetime probability of relapse after 1 year of
validated abstinence [8, 10].
Our assessment of the eﬀects of smoking cessation on mortality
rate was based on the results of the American Cancer Society
Prevention Study II, as described in the 1990 report of U.S. Sur-
geon General [19]. This study compared mortality rates for
smokers and never-smokers, through age 75 years. Based on Swiss
mortality data, we extrapolated the eﬀects of cessation on mortality
to extend the mortality curve for smokers through age 100 years.
Previous studies have found that the mortality rate for former
smokers, whatever the level of previous consumption, progressively
approaches and ﬁnally rejoins the mortality rate for never-smokers
approximately 20 years after quitting [19, 21, 22]. Based on the
ﬁndings of the American Cancer Society’s study, we assumed a
conservative approach and applied a phase-in period to never-
smokers mortality risk of 25 years after quitting for formers
smokers who used to smoke on average 20 cigarettes a day [19]. We
projected the mortality rate for former smokers during the phase-in
period by calculating a weighted average of the incremental dif-
ferentials between mortality rates of never-smokers and smokers,
weighted according to the duration of abstinence.
Cost of smoking cessation therapies
In ﬁguring medical and non-medical costs of smoking cessation
therapies, we assumed a third-party-payer perspective, an approach
used in several previous cost-eﬀectiveness analyses of NRT [9, 10].
This approach allowed us to compare our results with those of
existing studies.
We based the dosage and duration of each pharmacological
treatment on current clinical guidelines, which recommend that
treatment can last up to 3 months [3]. Physicians commonly rec-
ommend that treatment last for a minimum of 1 month, so we
assumed that all smokers who agree to undergo treatment incur the
cost of at least 1 month of therapy. Previous studies suggest that
50% of smokers who initiate treatment continue for a second
month, and only 30% of those who start continue for a third
month [23, 24]. These ﬁgures reﬂect the signiﬁcant rate of relapse
within the ﬁrst several weeks of cessation therapy.
We estimated the price of each treatment based on 2001 phar-
macy list prices provided in the drug therapy book for Switzerland
[25]. We based the costs associated with GPs’ time on average
hourly fees in 2001 for medical consultations that do not include
any technical procedures [26], as generally performed for other
preventive interventions [27]. Cessation counselling and recom-
mendations for pharmacological treatment were delivered by GPs
during routine oﬃce visits. We assumed that the initial cessation
counselling lasted approximately 10 min for all patients. If a
patient agreed to undergo pharmacological treatment, an addi-
tional 15 min of the GP’s time was required during the ﬁrst con-
sultation, as well as ﬁve 15-min follow-up consultations to take
place during the remaining course of treatment. In total, pharma-
cological treatment required an additional 90 min of GP consul-
tation relative to cessation counselling only. Details regarding
treatment costs, dosages and duration are detailed elsewhere [28].
Discounting and currency conversion
In this analysis, there is a long period of time between the point at
which the costs of the interventions incur and the point at which the
beneﬁts in life-years saved are realised. For this reason, it is nec-
essary to calculate the present discounted value of these delayed
beneﬁts so that the value of life-years saved is measured on the
same relative scale as the cost of the intervention at the time it is
undertaken [29, 30]. We applied a 3% discount rate, which is
commonly used in these types of prospective cost-eﬀectiveness
analyses [29]. To facilitate cross-country comparisons, we con-
ducted the analysis and yielded our initial results using US dollars
for all cost data. We then converted all results into Euros ( ) by
calculating the mean of average monthly exchange rates for 2002,
which was 1.0612 Euros to 1 US dollar.
Sensitivity analysis
We subjected each input variable in our analysis to sensitivity
analysis, which provides an important range of possible results
when the input variables are not constant. Sensitivity analysis also
reveals which variables are most inﬂuential in determining an
intervention’s cost-eﬀectiveness.
Results
The cost per life-year saved for only counselling ranges
from 385 (age 45–49 years) to 622 (age 65–69 years)
for men and from 468 (age 50–54 years) to 796 (age
25–29 years) for women (Table 2). Pharmacological
therapy used in addition to counselling increases
smokers’ chances of successful cessation, which, in turn,
increases their potential number of life-years saved due
to quitting. The cost-eﬀectiveness ratios (Table 3) must
be interpreted in marginal terms and reﬂect only the
additional costs and beneﬁts derived from supplemental
pharmacological treatment. The marginal cost per life-
year saved varies according to treatment, but, in each
case, treatment as an adjunct to counselling yields a
greater number of life-years saved relative to average
gains from counselling only. The cost-eﬀectiveness ratios
for the ﬁve pharmacological treatments vary from 1768
to 6879 for men, and from 2146 to 8799 for women.
The most cost-eﬀective treatment is bupropion, followed
by the patch, and then, in descending order, the spray,
the inhaler and, lastly, gum. There is a consistent dif-
ference in cost-eﬀectiveness between men and women
across all treatments, which proceeds directly from the
Table 2 Cost per life-year saved of counselling only (in Euro)
Age category (years) Men Women
25–29 540 796
30–34 481 682
35–39 434 595
40–44 402 531
45–49 385 488
50–54 388 468
55–59 418 473
60–64 487 510
65–69 622 596
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shape of their respective mortality curves. The number
of cigarettes smoked tends to be higher among men than
women. Men, therefore, stand to gain more units of
beneﬁt—life-years saved—from cessation, which yields
lower cost-eﬀectiveness ratios than for women.
Table 3 also shows the signiﬁcant diﬀerences in cost-
eﬀectiveness according to the age of patients at the time
of the intervention. Among men, the cost-eﬀectiveness
ratio is lowest for each treatment in the 45- to 49-year-
old group. For women, the ratio is lowest in each case
among the 50- to 54-year-olds. All treatments become
progressively less cost-eﬀective as patient age both
decreases and increases from the middle-aged groups.
Discounting diminishes the cost-eﬀectiveness for the
youngest smokers. For the oldest smokers, the greater
probability that they will die before realising the beneﬁts
of quitting diminishes the cost-eﬀectiveness.
There is also signiﬁcant variation in cost-eﬀectiveness
among the ﬁve treatments, which is primarily due to
diﬀerences in retail prices. For example, the treatment
cost for a 3-month course of the nicotine patch is
354.54, while the retail price for the same course of
treatment with the nicotine nasal spray is 743.02.
Notably, physicians’ salaries do not account for a sig-
niﬁcant part of the variation in cost-eﬀectiveness between
the various pharmacological therapies in each country.
Sensitivity analysis changes in treatment eﬀectiveness
produce major eﬀects for the three recently approved
treatments in both countries (i.e., spray, inhaler and
bupropion) (Table 4). We based our sensitivity analysis
for eﬀectiveness of the treatments on the 95% conﬁdence
intervals (CIs) for their respective odds ratios. Very few
studies have been conducted regarding the eﬀectiveness
of the spray, inhaler and bupropion, and, consequently,
their 95% CIs are large. Therefore, the sensitivity anal-
ysis for eﬀectiveness of these three treatments produced a
signiﬁcantly wide range of results. This analysis also
demonstrates the strong inﬂuence of the discount rate
and natural quit rate on the cost-eﬀectiveness of phar-
macological treatments. When a 0% discount rate is
applied, cost-eﬀectiveness increases for all ﬁve treatments
by more than 60%. The change in cost-eﬀectiveness from
varying the natural quit rate between 1% and 4% is also
quite signiﬁcant, resulting in an overall 35% increase in
cost-eﬀectiveness. For example, the ratios for the nico-
tine patch range from 1730 (4% quit rate) to 4789 (1%
quit rate) for men, and from 2281 (4%) to 6009 (1%),
for women. Changes in the physicians’ fees and treatment
costs have minor eﬀects on the cost-eﬀectiveness ratios
for the respective treatments (data not shown).
Discussion
Our results provide a comparison of cost-eﬀectiveness
between the ﬁve ﬁrst-line smoking cessation therapies.
The nicotine patch and bupropion are the most cost-
eﬀective pharmacological treatments. The eﬃcacy of the
patch is based on a meta-analysis of 23 studies and has a
very narrow conﬁdence interval. The cost-eﬀectiveness
results for the patch are, therefore, quite robust. The
results for bupropion are promising, although it would
be premature to draw ﬁnal conclusions based on a
limited meta-analysis [3]. Additional data will strengthen
the validity of our ﬁndings; but, until further eﬃcacy
results are available, sensitivity analysis provides an
important range of possible results for the cost-eﬀec-
tiveness of bupropion.
Nicotine spray, inhaler, and gum are less cost-eﬀective
than the patch or bupropion. The evidence for eﬀec-
tiveness is strong for both the inhaler and spray, but
prices for these two treatments are signiﬁcantly higher
than the others. This raises their respective cost-eﬀec-
tiveness ratios. The eﬀectiveness of the gum is the
Table 3 Incremental cost per
life-year saved of pharma-
cological smoking cessation
treatments (in Euro)
Age category (years) Gum Patch Spray Inhaler Bupropion
Men Women Men Women Men Women Men Women Men Women
25–29 5969 8799 4356 6423 5135 7570 5178 7634 2474 3646
30–34 5316 7540 3880 5503 4573 6487 4612 6542 2202 3125
35–39 4804 6571 3506 4795 4132 5652 4168 5700 1990 2722
40–44 4448 5864 3246 4280 3826 5044 3858 5088 1842 2429
45–49 4266 5399 3113 3941 3669 4645 3700 4684 1768 2237
50–54 4298 5178 3137 3779 3698 4454 3729 4492 1781 2146
55–59 4623 5230 3374 3816 3977 4499 4011 4537 1916 2166
60–64 5388 5640 3933 4116 4635 4851 4675 4893 2232 2337
65–69 6879 6588 5021 4809 5918 5667 5968 5715 2851 2730
Table 4 Sensitivity of the cost-
eﬀectiveness ratio according to
the 95% conﬁdence interval for
the eﬃcacy studies (in Euro)
Gum Patch Nasal spray Inhaler Bupropion
Men Women Men Women Men Women Men Women Men Women
CE ratio 45-year-old 4860 6258 3547 4567 4181 5384 4216 5429 2014 2593
Lower bound 6212 7999 4633 5966 8700 11,201 10,614 13,666 6308 8121
Upper bound 3901 5024 2799 3605 2469 3179 2298 2959 960 1237
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weakest of the ﬁve treatments, which explains its
relatively high cost-eﬀectiveness ratio. It is important to
note that in the case of the spray, inhaler and gum,
smokers are able to adjust the quantity of treatment they
consume based on their individual needs. For this reason,
costs may vary substantially between individuals.
We made conservative estimates for the dose and
duration of treatment, assuming the highest and longest
dosage recommended in recent clinical guidelines [3].
Prices in Switzerland for the ﬁve ﬁrst-line treatments are
quite stable, both between pharmacies and over time. In
other countries, where competition between pharmacies
and promotional oﬀers keep prices very ﬂexible, the sit-
uationmight diﬀer. The eﬀects of intense competition and
the introduction of generic NRT products may induce
suﬃcient pressure on the market to drive the prices down,
which could, in turn, lower the cost-eﬀectiveness ratios.
There is continuing debate regarding the real and
signiﬁcant diﬀerence in lifetime medical expenditures
between smokers and non-smokers. The 1992 report of
the US Surgeon General reported that the average life-
time medical costs for a smoker exceeds that of a non-
smoker by more than US $6000 ( 7250 in 2002) [31].
Other studies, however, have arrived at the inverse
conclusion, suggesting that lifetime medical expenditures
are higher for non-smokers than for smokers, due, in
part, to the fact that smokers live, on average, fewer
years than do non-smokers [32, 33]. To our knowledge,
no reliable and deﬁnitive data exist regarding the lifetime
medical expenditures of former smokers. Therefore, as
in other smoking cessation cost-eﬀectiveness research
[8, 9, 10], we made the conservative assumption that
there are no savings in lifetime medical expenditures
associated with quitting smoking.
Our evidence for the cost-eﬀectiveness of pharmaco-
logical cessation therapies is most pointed when
presented in comparison with other common health
interventions. For example, a 1991 New Zealand cost-
eﬀectiveness analysis demonstrated that the cost per
quality-adjusted life-year saved associated with phar-
macological hypertension treatments ranged from UK
£11,058 to UK £194,989 ( 28,187 to 497,036 in 2002 )
[34]. For pharmacological hypercholesterolemia primary
prevention treatments, a 1995 Canadian study found the
cost per life-year saved to range from CAD $17,231 to
CAD $155,891 ( 17,238 to 155,953 in 2002 ) [35], and a
2000 US study found the cost per quality-adjusted life-
year saved to range from US $54,000 to US $1,400,000
( 53,161 to 1,378,238 in 2002 ) [36]. Furthermore,
hypertension and hypercholesterolemia treatments (and
their costs) continue throughout the remainder of the
patient’s life, while smoking cessation treatment (and its
costs) lasts only few months. This results in a substantial
diﬀerence in total lifetime expenditures per patient
between the two interventions.
It may also be useful to compare our results with
existing cost-eﬀectiveness analyses of NRT, bearing in
mind that methodological diﬀerences play a signiﬁcant
role in the variation across results. One study found the
incremental cost per life-year saved associated with
nicotine gum to range from US $4167 to US $9473
( 6445 to 14,652 in 2002 ) [9]. Two other studies found
the incremental cost per life-year saved associated with
the nicotine patch to be US $1796 to US $4391 ( 1897 to
4638 in 2002 ) and US $4390 to US $10,943 ( 4743 to
11,823 in 2002 ), respectively [8, 10]. A 2002 study
calculated the incremental cost per life-year saved
associated with bupropion to be from US $920 to US
$2150 ( 867 to 2,026) [37].
It is important to acknowledge that some smokers
may initiate use of over-the-counter (OTC) NRT inde-
pendently, thereby missing the beneﬁt of adjunctive ces-
sation counselling provided by physicians [38]. This may
lessen the eﬀectiveness of the OTC treatments relative to
the treatments that are available only by prescription.
Prescription requirements allow physicians to ensure that
smoking cessation protocols are carried out as intended.
We concluded that the use of quality-adjusted life years
was not warranted in this analysis since the intervention
does not have a negative eﬀect on quality of life. The
pharmacological treatments have very few side eﬀects,
and any that may occur are limited to the short course of
treatment. Provided the contraindications are respected,
only bupropion has minor signiﬁcant side eﬀects (e.g.,
insomnia). The proportion of patients who cannot toler-
ate side eﬀects is captured in the respective treatment
eﬃcacy odds ratios and is thereby accounted for in our
analysis. We assumed in our model that the shape of the
mortality curve for smokers is simply moved forward in
time because of premature death from smoking, versus
having a diﬀerent shape from that of a non-smoker. We
determined, then, that the use of life-years-saved is ade-
quate for estimating the beneﬁts of quitting smoking.
One limitation of our study was that we were not able
to account for variations in treatment eﬀectiveness across
individuals. There are many patient variables that may be
associated, both independently and in interaction, with a
treatment’s potential eﬀectiveness [38], such as age and
cigarette consumption, as well as factors of socioeco-
nomic status, culture, race and ethnicity. Until clinical
trials have been conducted that account for these inﬂu-
ences, treatment eﬃcacy can only be rightly translated
into eﬀectiveness for simulated cohorts that match ex-
actly the proﬁles of study populations used in the existing
clinical experiments. Another limitation is that the lack of
mortality data for smokers over age 75 years made it very
diﬃcult to evaluate the years of life saved for the oldest
groups of smokers. We, therefore, developed conserva-
tive hypotheses, particularly important in light of our
assumption that the mortality of ex-smokers rejoins that
of non-smokers 25 years after quitting. Furthermore, we
did not include the life-years saved for those smokers who
relapse after several years of abstinence. Finally, we only
considered savings in mortality and did not include any
averted morbidity that is attributable to treatment. Dis-
ability-adjusted life-years account for averted death and
disability, and would very likely yield better cost-eﬀec-
tiveness ratios in this type of analysis.
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We conclude that the cost-eﬀectiveness of ﬁrst-line
treatments for nicotine dependence varied widely with
age and sex and was sensitive to the assumption on the
natural quit rate. Bupropion and the nicotine patch were
the two most cost-eﬀective treatments. These ﬁndings
may be useful to policymakers in the public and private
sectors (e.g., government health systems, health insur-
ance beneﬁts planners) in their eﬀorts to reduce smoking
prevalence.
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